Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0QTTWI
ADC Name	Praluzatamab ravtansine
Synonyms	Anti-CD166-DM4-CX-2009; CX-2009; Anti-cd166 probody-drug conjugate cx-2009; CD166 Probody Drug Conjugate; CD166 probody drug conjugate Click to Show/Hide
Organization	ImmunoGen, Inc.; CytomX Therapeutics, Inc.
Drug Status	Phase 2
Indication	In total 7 Indication(s) Biliary tract cancer [ICD11:2C15] Phase 2 Breast cancer [ICD11:2C60-2C65] Phase 2 Head and neck cancer [ICD11:2B60-2B6E] Phase 2 Non-small cell lung cancer [ICD11:2C25] Phase 2 Ovarian cancer [ICD11:2C73] Phase 2 Solid tumors [ICD11:2A00-2A0Z\|2B50-2F9Z] Phase 2 Triple negative breast cancer [ICD11:2C60-2C65] Phase 2
Drug-to-Antibody Ratio	3.5
Structure
	3D MOL	2D MOL
Antibody Name	Praluzatamab		Antibody Info
Antigen Name	CD166 antigen (ALCAM)		Antigen Info
Payload Name	Mertansine DM4		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)		Linker Info
Conjugate Type	Random conjugation through nucleophilic lysines.
Combination Type	Ravtansine
Puchem SID	472423424 , 402425941 , 404719323
Drugbank ID	DB16090
ChEBI ID	CHEMBL4297736

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Partial Response (PR)	NCT03149549	Phase 1/2	A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors (PROCLAIM-CX-2009). Click to Show/Hide

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Partial Response (PR)	9.00%
Patients Enrolled	Eastern Cooperative Oncology Group (ECOG) 0, 1, metastatic or locally advanced unresectable solid tumors with progressive disease (PD) after standard treatment or known intolerance to available treatment, based on the predicted prevalence of CD166 expression, were breast cancer, castration-resistant prostate cancer, nonsmall cell lung cancer (NSCLC), epithelial ovarian cancer, head and neck squamous cell cancer (HNSCC), cholangiocarcinoma, and endometrial carcinoma. Click to Show/Hide
Administration Dosage	Scalating doses every 3 weeks (0.25-10 mg/kg) or every 2 weeks (4-6 mg/kg), IV.
*Related Clinical Trial*
NCT Number	NCT03149549	Clinical Status	Phase 1/2
Clinical Description	A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors (PROCLAIM-CX-2009).
Primary Endpoint	Median number of prior therapies was 5. On the basis of tolerability, the RP2D was 7 mg/kg every 3 weeks. Tumor regressions were observed at doses 4 mg/kg.

References

Ref 1	Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 May 13;28(10):2020-2029.